echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Eur Urol: Differential Response Analysis of Different Molecular Subtypes of Urothelial Carcinoma to Neoadjuvant Chemotherapy

    Eur Urol: Differential Response Analysis of Different Molecular Subtypes of Urothelial Carcinoma to Neoadjuvant Chemotherapy

    • Last Update: 2021-12-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Neoadjuvant chemotherapy is one of the few treatment options with the highest level of evidence in the treatment of myometrial invasive bladder cancer (MIBC), but before radical cystectomy (RC) treatment, the use of neoadjuvant chemotherapy is still less
    .


    The reason for the low use rate of neoadjuvant chemotherapy is that the treatment-related toxicity and absolute survival benefit are not high, ranging from 5% to 10%


    It has not been used clinically to reduce biomarkers over-treatment of non-responders, represents a major challenge to medical needs and a study of unmet has not been used clinically to reduce biomarkers nonresponders over-treatment, representing a Unmet medical needs and major research challenges

    Currently, for myometrial invasive bladder cancer (MIBC), there are no tissue biomarkers that can be used to clinically predict the response to neoadjuvant chemotherapy
    .

    Recently, researchers from Sweden published an article on the "Eur Urol" magazine, investigated how different molecular subtypes influence pathological response and students before preoperative chemotherapy of cisplatin deposit rate
    .

    We investigated how different molecular subtypes influence pathological response and students before preoperative chemotherapy of cisplatin deposit rate investigated how different molecular subtypes influence pathological response and students before preoperative chemotherapy of cisplatin deposit rate deposit

    The researchers used tumor transcriptome analysis and immunostaining to classify a retrospective cohort of 149 patients
    .


    A cohort of only radical cystectomy and public data sets were used for comparison and external verification


    The results showed that after neoadjuvant chemotherapy and radical cystectomy, patients with genomic instability (GU) and epithelial (Uro) tumors had a higher proportion of complete pathological responses (16/31 [52%] and 17/54, respectively [ 31%]), and the proportion of complete pathological responses in patients with the basal/squamous (Ba/Sq) subtype was 5/21 (21%)
    .


    After adjusting the clinical stage, compared with Ba/Sq tumors, molecular subtypes were compared with GU tumors (hazard ratio [HR] 0.


    Molecular subtypes and clinical staging are related to cancer-specific survival of neoadjuvant chemotherapy

    Molecular subtypes and clinical staging are related to cancer-specific survival of neoadjuvant chemotherapy

    In summary, the luminal urothelial carcinoma subtype has a stronger response to neoadjuvant chemotherapy based on cisplatin
    .


    The second-generation subtype-specific biomarkers, such as SPP1, may be a direction for the development of more precise treatments in MIBC neoadjuvant chemotherapy


    The luminal urothelial carcinoma subtype has a stronger response to neoadjuvant chemotherapy based on cisplatin


    Original source:

    Original source:

    Gottfrid Sjödahl, Johan Abrahamsson, Karin Holmsten et al.


    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.